Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations

Clonal hematopoiesis (CH) refers to age‐associated expansion of somatic variants in hematopoietic stem and progenitor cells (HSPC).

[1]  P. Natarajan,et al.  Interleukin-6 Receptor Polymorphism Attenuates Clonal Hematopoiesis-Mediated Coronary Artery Disease Risk Among 451 180 Individuals in the UK Biobank. , 2023, Circulation.

[2]  V. Fuster,et al.  TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease , 2023, Nature Cardiovascular Research.

[3]  A. Bick,et al.  Genetic causes and cardiovascular consequences of clonal hematopoiesis in the UK Biobank , 2022, Nature Cardiovascular Research.

[4]  Christopher A. Miller,et al.  Clonal Hematopoiesis and Risk of Incident Lung Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Marchini,et al.  Common and rare variant associations with clonal haematopoiesis phenotypes , 2022, Nature.

[6]  D. Neuberg,et al.  Prediction of risk for myeloid malignancy in clonal hematopoiesis. , 2022, NEJM evidence.

[7]  M. Endres,et al.  Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. , 2022, Blood.

[8]  D. Cilloni,et al.  Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis , 2022, Haematologica.

[9]  Annette S. Kim,et al.  Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19 , 2022, Blood.

[10]  E. Wieben,et al.  Enhancer deregulation in TET2 Mutant Clonal Hematopoiesis is associated with increased COVID-19 related inflammation severity and mortality , 2022, bioRxiv.

[11]  M. Hathcock,et al.  Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma , 2022, Blood Cancer Journal.

[12]  M. Loh,et al.  International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.

[13]  D. Neuberg,et al.  TET2-mutant clonal hematopoiesis and risk of gout , 2022, Blood.

[14]  T. Witzig,et al.  Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with TET2-mutant clonal cytopenias of undetermined significance. , 2022, Journal of Clinical Oncology.

[15]  J. Manson,et al.  Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics , 2022, Immunity & ageing : I & A.

[16]  C. Flowers,et al.  Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. , 2022, Blood cancer discovery.

[17]  M. Patnaik,et al.  Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders , 2022, Current Hematologic Malignancy Reports.

[18]  Andrew T Nguyen,et al.  Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms , 2022, Blood.

[19]  Aviv Madar,et al.  TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. , 2022, JAMA cardiology.

[20]  B. Kestenbaum,et al.  Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease , 2022, Journal of the American Society of Nephrology : JASN.

[21]  P. Campbell,et al.  Life histories of myeloproliferative neoplasms inferred from phylogenies , 2022, Nature.

[22]  C. Thiede,et al.  Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment , 2022, Blood advances.

[23]  V. Iyer,et al.  Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis , 2022, Nature Genetics.

[24]  Ashutosh Kumar Singh,et al.  Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy , 2022, JCO precision oncology.

[25]  P. Campbell,et al.  The longitudinal dynamics and natural history of clonal haematopoiesis , 2021, Nature.

[26]  Andrew D. Johnson,et al.  Clonal Hematopoiesis Is Associated With Higher Risk of Stroke , 2021, Stroke.

[27]  Ansuman T. Satpathy,et al.  Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease , 2021, Blood.

[28]  L. Zon,et al.  Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis , 2021, Science.

[29]  David M. Evans,et al.  Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis , 2021, The Journal of experimental medicine.

[30]  B. Ebert,et al.  Distinction of lymphoid and myeloid clonal hematopoiesis , 2021, Nature Medicine.

[31]  A. Tinker,et al.  Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. , 2021, JAMA oncology.

[32]  Tyler J Dougan,et al.  Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation , 2021, medRxiv.

[33]  Sina A. Gharib,et al.  Association of clonal hematopoiesis with chronic obstructive pulmonary disease , 2021, Blood.

[34]  D. Neuberg,et al.  Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. , 2021, Blood advances.

[35]  G. Garcia-Manero,et al.  Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation , 2021, Leukemia.

[36]  Nicholas D. Camarda,et al.  Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome , 2021, Nature Communications.

[37]  R. Fonseca,et al.  Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy , 2021, American journal of hematology.

[38]  P. Awadalla,et al.  Clonal hematopoiesis is associated with risk of severe Covid-19 , 2020, Nature Communications.

[39]  P. Shah,et al.  Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders , 2021 .

[40]  A. Zeiher,et al.  Clonal Hematopoiesis–Driver DNMT3A Mutations Alter Immune Cells in Heart Failure , 2020, Circulation research.

[41]  P. Nelson,et al.  Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference , 2020, JAMA oncology.

[42]  Stuart M. Gardos,et al.  Cancer therapy shapes the fitness landscape of clonal hematopoiesis , 2020, Nature Genetics.

[43]  Ivana V. Yang,et al.  Inherited causes of clonal haematopoiesis in 97,691 whole genomes , 2020, Nature.

[44]  G. Getz,et al.  Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant , 2020, Nature Communications.

[45]  M. M. van der Klauw,et al.  Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. , 2020, Blood.

[46]  T. Druley,et al.  The evolutionary dynamics and fitness landscape of clonal hematopoiesis , 2020, Science.

[47]  J. W. Hansen,et al.  Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study , 2020, Leukemia.

[48]  Lisa M Haley,et al.  Cancer spectrum and outcomes in the Mendelian short telomere syndromes. , 2020, Blood.

[49]  T. Druley,et al.  Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation , 2020, Science Translational Medicine.

[50]  S. Gabriel,et al.  Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis , 2019, Circulation.

[51]  B. Ebert,et al.  Clonal hematopoiesis in human aging and disease , 2019, Science.

[52]  William J. Hogan,et al.  Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. , 2019, Mayo Clinic proceedings.

[53]  Liying Zhang,et al.  Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. , 2019, Blood advances.

[54]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[55]  O. Pietiläinen,et al.  Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans , 2019, Nature Communications.

[56]  Annette S. Kim,et al.  Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy , 2019, British journal of haematology.

[57]  Abdul Waheed Khan,et al.  Shwachman‐Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability , 2019, British journal of haematology.

[58]  L. Bullinger,et al.  Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  B. Brüne,et al.  Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure , 2018, JAMA cardiology.

[60]  A. Tall,et al.  Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2V617F Mice , 2018, Circulation research.

[61]  Michael R. Green,et al.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. , 2018, Cancer discovery.

[62]  J. Scott,et al.  Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes , 2018, Mayo Clinic proceedings.

[63]  Stanley W. K. Ng,et al.  Prediction of acute myeloid leukaemia risk in healthy individuals , 2018, Nature.

[64]  K. Ballman,et al.  Somatic mutations precede acute myeloid leukemia years before diagnosis , 2018, Nature Medicine.

[65]  J. Ross,et al.  Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. , 2018, Blood.

[66]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[67]  J. Cerhan,et al.  Long‐Term Follow‐up of Monoclonal Gammopathy of Undetermined Significance , 2018, The New England journal of medicine.

[68]  B. Alter.  Inherited bone marrow failure syndromes: considerations pre- and posttransplant. , 2017, Hematology. American Society of Hematology. Education Program.

[69]  O. Abdel-Wahab,et al.  Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression , 2017, Cell.

[70]  M. Ladanyi,et al.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. , 2017, Cell stem cell.

[71]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[72]  M. Cazzola,et al.  Clinical significance of somatic mutation in unexplained blood cytopenia. , 2017, Blood.

[73]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[74]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[75]  A. LaCasce,et al.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  H. McLeod,et al.  Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. , 2017, The Lancet. Oncology.

[77]  J. Soulier,et al.  How I treat MDS and AML in Fanconi anemia. , 2016, Blood.

[78]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[79]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[80]  B. Alter.  Fanconi anemia and the development of leukemia. , 2014, Best practice & research. Clinical haematology.

[81]  T. Soussi,et al.  TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade , 2014, Human mutation.

[82]  L V Vinokurova,et al.  [Shwachman-Diamond syndrome]. , 2014, Terapevticheskii arkhiv.

[83]  L. Staudt,et al.  EZH2 mutations are frequent and represent an early event in follicular lymphoma. , 2013, Blood.

[84]  E. Riboli,et al.  Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications , 2013, Nature Genetics.

[85]  S. Bojesen,et al.  Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population , 2013, British journal of haematology.

[86]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[87]  K. Akashi,et al.  Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. , 2011, Cancer cell.

[88]  B. Alter,et al.  Pathophysiology and management of inherited bone marrow failure syndromes. , 2010, Blood reviews.

[89]  P. Rosenberg,et al.  Cancer in dyskeratosis congenita. , 2009, Blood.

[90]  M. Ladanyi,et al.  Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[91]  Yolanda F. Darlington,et al.  The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways , 2008, Cancer and Metastasis Reviews.

[92]  C. Harrison,et al.  Acquired skewing of X‐chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age , 1997, British journal of haematology.

[93]  R. Kelly,et al.  Cytokines and cardiac contractile function. , 1997, Circulation.

[94]  D. Gilliland,et al.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. , 1996, Blood.